HUP9800757A2 - Intima-hipertrófia gátló oxindolszármazékokat tartalmazó gyógyszerkészítmények - Google Patents

Intima-hipertrófia gátló oxindolszármazékokat tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9800757A2
HUP9800757A2 HU9800757A HUP9800757A HUP9800757A2 HU P9800757 A2 HUP9800757 A2 HU P9800757A2 HU 9800757 A HU9800757 A HU 9800757A HU P9800757 A HUP9800757 A HU P9800757A HU P9800757 A2 HUP9800757 A2 HU P9800757A2
Authority
HU
Hungary
Prior art keywords
powder
substituted
low carbon
carbon atom
pipe
Prior art date
Application number
HU9800757A
Other languages
English (en)
Inventor
Tetsuji Asao
Yuichi Hagiwara
Makoto Kitade
Atsushi Sato
Yasundo Yamazaki
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of HUP9800757A2 publication Critical patent/HUP9800757A2/hu
Publication of HUP9800757A3 publication Critical patent/HUP9800757A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

A találmány tárgya intima hipertrófia gátló hatásúgyógyszerkészítmények, amelyek hatóanyagként, valamely (1) általánősképletű őxindől származékőt tartalmaznak, ahől a képletbenR1 jelentése hidrőgénatőm; helyettesített fenilcsőpőrt vagy adőttesetben helyettesített piridilcsőpőrt,R2 jelentése adőtt esetben helyettesített fenilcsőpőrt; vagy adőttesetben helyettesített piridilcsőpőrt;R3 jelentése hidrőgénatőm; kis szénatőmszámú alkilcsőpőrt,benzilcsőpőrt adőtt esetben helyettesített benzől-szűlfőnil-csőpőrt;vagy acilcsőpőrt;R4 hidrőgénatőm; kis szénatőmszámú alkőxicsőpőrt, halőgénatőm,aminőcsőpőrt, kis szénatőmszámú alkil-aminő-csőpőrt, karbamőilcsőpőrt,kis szénatőmszámú karbőxi-karbőnil-csőpőrt; adőtt esetbenhelyettesített fenil-karbamőil-csőpőrt; vagy triflűőr-metil-csőpőrt;X jelentése CH vagy N;n jelentése 0-4 közötti egész szám, mely szám a szűbsztitűensek számátjelzi; és a szaggatőtt/tömött kettős vőnal jelentése egyes vagy kettőskötés.A találmány szerinti intima hipertrófia gátlók a prőlifelatívérbetegségek, így a PTCA űtáni resztenőzis, arteriőszklerózis,perifériás embólia és angiitis indikációbanpreventív/terápiás/feljavító szerként használhatók.ŕ
HU9800757A 1996-01-17 1997-01-16 Intimal thickening inhibitors containing oxyindole derivatives and pharmaceutical compositions containing them HUP9800757A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP569396 1996-01-17

Publications (2)

Publication Number Publication Date
HUP9800757A2 true HUP9800757A2 (hu) 1998-07-28
HUP9800757A3 HUP9800757A3 (en) 1998-08-28

Family

ID=11618190

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800757A HUP9800757A3 (en) 1996-01-17 1997-01-16 Intimal thickening inhibitors containing oxyindole derivatives and pharmaceutical compositions containing them

Country Status (12)

Country Link
US (1) US5977130A (hu)
EP (1) EP0815859B1 (hu)
KR (1) KR100264807B1 (hu)
AT (1) ATE243034T1 (hu)
AU (1) AU708167B2 (hu)
CA (1) CA2214759C (hu)
DE (1) DE69722858T2 (hu)
ES (1) ES2201266T3 (hu)
HU (1) HUP9800757A3 (hu)
NO (1) NO315688B1 (hu)
RU (1) RU2145852C1 (hu)
WO (1) WO1997025986A1 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
US6828344B1 (en) * 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CN1158283C (zh) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CN1295216C (zh) * 2003-07-04 2007-01-17 中国人民解放军军事医学科学院毒物药物研究所 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途
WO2005018531A2 (fr) * 2003-08-26 2005-03-03 'chemical Diversity Research Institute', Ltd. Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants
WO2006105795A1 (en) * 2005-04-08 2006-10-12 Leo Pharma A/S Novel indolinone derivatives
WO2011032320A1 (en) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Novel alkene oxindole derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3413299A (en) * 1963-07-11 1968-11-26 Upjohn Co 3', 3'-di-substituted[spiro-indoline-3, 2'-oxiran]-2 ones and derivatives
US3428649A (en) * 1968-01-23 1969-02-18 Mcneilab Inc Oxindole derivatives
US3725403A (en) * 1970-10-20 1973-04-03 Squibb & Sons Inc Benzothiazine derivatives
US4002749A (en) * 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
JPS6229570A (ja) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd 3,5−ジイソプロピルベンジリデン複素環式化合物
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors
WO1991001306A1 (fr) * 1989-07-25 1991-02-07 Taiho Pharmaceutical Company, Limited Derive oxoindole
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
JP3130342B2 (ja) * 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
CA2214759C (en) 2004-05-18
DE69722858T2 (de) 2004-05-13
EP0815859A1 (en) 1998-01-07
NO974280D0 (no) 1997-09-16
CA2214759A1 (en) 1997-07-24
DE69722858D1 (de) 2003-07-24
EP0815859A4 (en) 2001-04-11
ATE243034T1 (de) 2003-07-15
NO974280L (no) 1997-11-11
EP0815859B1 (en) 2003-06-18
HUP9800757A3 (en) 1998-08-28
KR19980703023A (ko) 1998-09-05
ES2201266T3 (es) 2004-03-16
KR100264807B1 (ko) 2000-09-01
AU708167B2 (en) 1999-07-29
RU2145852C1 (ru) 2000-02-27
AU1398697A (en) 1997-08-11
US5977130A (en) 1999-11-02
NO315688B1 (no) 2003-10-13
WO1997025986A1 (fr) 1997-07-24

Similar Documents

Publication Publication Date Title
HUP9800757A2 (hu) Intima-hipertrófia gátló oxindolszármazékokat tartalmazó gyógyszerkészítmények
HUP0102472A2 (hu) Nitrogén-oxid szintáz inhibitorként alkalmazható amidinoszármazékok, eljárás az előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0003731A2 (hu) 4-Bróm- vagy 4-jód-fenil-amino-benzhidroxámsav-származékok és ilyen vegyületek MEK gátlóként való alkalmazása
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
HUP9902459A2 (hu) Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására
YU69991A (sh) Derivati piridina
DK0553191T3 (da) Pyridin- og pyridin-N-oxidderivater af diarylmethylpiperidiner eller -piperaziner, præparater og an vendelse deraf
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
DK0490772T3 (da) 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem
YU47116B (sh) Postupak za dobijanje novih n-supstituisanih benzimidazolskih derivata
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
HUP9900607A2 (hu) Pirido[2,3-d]-pirimidin-származékok és a vegyületeket tartalmazó gyógyászati készítmények
DE68902301T2 (de) Diarylverbindungen als antiatherosklerotische mittel.
HUP0203054A2 (hu) Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
ATE233754T1 (de) Diphenyl-piperidin derivate
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
SE8002322L (sv) Medel for behandling av inflammatoriska tarmsjukdomar
HUP0102025A2 (hu) Diaril-1,3,4-oxadiazolon-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JO2471B1 (en) Antibacterial pharmaceutical compound.
FR2508033B1 (hu)
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
HUP9904056A2 (hu) Farnezil-protein-transzferáz inhibitor hatású szubsztituált benzo-ciklohepta-piridin-származékok és alkalmazásuk
HUP0203118A2 (hu) Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk